New Jersey Assembly Bill A1150

New Jersey 2022-2023 Regular Session

• Introduced: 1/11/22
• Refer: 1/11/22

Caption

Prohibits investment by State of pension and annuity funds in Chinese pharmaceutical companies.

Impact

Should this bill be enacted into law, it will significantly alter investment strategies concerning the state’s pension and annuity funds. The Division of Investment in New Jersey will be tasked with divesting from any such companies within a timeframe of three years from the bill's effective date. This requirement aims to redirect state financial resources into local investments, particularly in New Jersey's pharmaceutical manufacturing sector, potentially benefiting the state economy and local jobs.

Summary

Assembly Bill A1150 aims to prohibit the investment of state pension and annuity funds in Chinese pharmaceutical companies. Introduced in the New Jersey legislature, the bill outlines the committee's concerns regarding investments in firms linked to the pharmaceutical sector in China, especially in light of issues raised during the COVID-19 pandemic. The legislation is predicated on the assertion that the Chinese government concealed critical information about the risks posed by the pandemic, which, the sponsors argue, justifies barring state funds from benefiting such entities.

Contention

While the bill has garnered support due to its strong nationalistic appeal against investing in Chinese firms amidst heightened geopolitical tensions, some critics argue that it may impact the overall diversification and returns of public pension funds. By limiting investment opportunities based on national origin rather than a firm's financial merit, opponents raise concerns about the potential long-term implications for state-funded retirements.